Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$11.21 USD

11.21
12,479,121

+0.12 (1.08%)

Updated Aug 12, 2022 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.75%
2Buy18.15%
3Hold9.70%
4Sell5.35%
5Strong Sell2.45%
S&P50010.91%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Generic Drugs

Trades from $1

Balance Sheet

Research for TEVA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Teva Pharmaceutical Industries Ltd falls in the month of December.

All items in Millions except Per Share data.

12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Assets          
Cash & Equivalents 2,165 2,177 1,975 1,782 963
Receivables 4,529 4,581 5,676 5,822 7,128
Notes Receivable 0 0 0 0 0
Inventories 3,818 4,403 4,422 4,731 4,924
Other Current Assets 2,059 1,844 1,391 1,459 2,367
Total Current Assets 12,573 13,005 13,464 13,794 15,382
Net Property & Equipment 5,982 6,296 6,436 6,868 7,673
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 596 695 386 368 574
Intangibles 27,506 29,547 36,078 38,922 46,054
Deposits & Other Assets 515 538 591 731 932
Total Assets 47,666 50,640 57,470 60,683 70,615
Liabilities & Shareholders Equity 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Notes Payable 0 0 0 0 0
Accounts Payable 1,686 1,756 1,718 1,853 2,069
Current Portion Long-Term Debt 1,426 3,188 2,345 2,216 3,646
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 2,771 2,465 2,562 2,738 3,563
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 5,144 5,757 7,048 7,515 8,643
Total Current Liabilities 11,027 13,164 13,674 14,322 17,921
Mortgages 0 0 0 0 0
Deferred Taxes/Income 784 964 1,096 2,140 3,277
Convertible Debt 0 0 0 0 0
Long-Term Debt 21,617 22,731 24,562 26,700 28,829
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2,578 2,240 2,640 1,727 1,843
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 36,422 39,579 42,407 44,889 51,870
Shareholders Equity 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Preferred Stock 0 0 0 0 3,631
Common Stock (Par) 57 57 56 56 54
Capital Surplus 27,561 27,443 27,312 27,210 23,479
Retained Earnings -10,529 -10,946 -6,956 -5,958 -3,803
Other Equity -1,717 -1,364 -1,221 -1,372 -467
Treasury Stock 4,128 4,128 4,128 4,142 4,149
Total Shareholder's Equity 11,244 11,061 15,063 15,794 18,745
Total Liabilities & Shareholder's Equity 47,666 50,640 57,470 60,683 70,615
Total Common Equity 11,244 11,061 15,063 15,794 15,114
Shares Outstanding 1,103.30 1,092.10 1,092.10 1,016.80 1,016.80
Book Value Per Share 10.19 10.13 13.79 15.53 14.86

Fiscal Year End for Teva Pharmaceutical Industries Ltd falls in the month of December.

All items in Millions except Per Share data.

6/30/2022 3/31/2022 12/31/2021 9/30/2021 6/30/2021
Assets          
Cash & Equivalents 2,058 2,175 2,165 2,045 2,436
Receivables 4,471 4,253 4,529 4,046 4,488
Notes Receivable 0 0 0 0 0
Inventories 4,049 4,012 3,818 4,167 4,362
Other Current Assets 1,586 2,010 2,059 1,896 1,535
Total Current Assets 12,164 12,451 12,573 12,154 12,822
Net Property & Equipment 5,740 5,932 5,982 6,040 6,127
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 1,595 637 596 622 645
Intangibles 25,537 27,102 27,506 28,011 28,541
Deposits & Other Assets 454 472 515 518 530
Total Assets 45,932 47,059 47,666 47,851 49,195
Liabilities & Shareholders Equity 6/30/2022 3/31/2022 12/31/2021 9/30/2021 6/30/2021
Notes Payable 0 0 0 0 0
Accounts Payable 1,901 1,750 1,686 1,514 1,551
Current Portion Long-Term Debt 1,719 2,077 1,426 2,709 3,530
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 2,579 3,078 2,771 2,590 2,318
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 4,796 4,707 5,144 5,011 5,291
Total Current Liabilities 10,996 11,613 11,027 11,825 12,691
Mortgages 0 0 0 0 0
Deferred Taxes/Income 532 666 784 910 932
Convertible Debt 0 0 0 0 0
Long-Term Debt 20,363 20,840 21,617 21,037 21,602
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 3,842 2,578 2,203 2,215
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 36,103 36,799 36,422 36,400 37,884
Shareholders Equity 6/30/2022 3/31/2022 12/31/2021 9/30/2021 6/30/2021
Preferred Stock 0 0 0 0 0
Common Stock (Par) 57 57 57 57 57
Capital Surplus 27,625 27,587 27,561 27,529 27,503
Retained Earnings -11,716 -11,484 -10,529 -10,370 -10,662
Other Equity -2,010 -1,771 -1,717 -1,636 -1,459
Treasury Stock 4,128 4,128 4,128 4,128 4,128
Total Shareholder's Equity 9,828 10,260 11,244 11,451 11,311
Total Liabilities & Shareholder's Equity 45,932 47,059 47,666 47,851 49,195
Total Common Equity 9,828 10,260 11,244 11,451 11,311
Shares Outstanding 1,103.30 1,103.30 1,103.30 1,103.00 1,102.80
Book Value Per Share 8.91 9.30 10.19 10.38 10.26